Get the Stockscreener App
2.123
9.66%
-0.227
After Hours:
2.22
0.097
+4.57%
Inmed Pharmaceuticals Inc stock is traded at $2.123, with a volume of 304.92K.
It is down -9.66% in the last 24 hours and down -2.17% over the past month.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
See More
Previous Close:
$2.35
Open:
$2.36
24h Volume:
304.92K
Relative Volume:
3.19
Market Cap:
$4.25M
Revenue:
$4.96M
Net Income/Loss:
$-6.82M
P/E Ratio:
-0.0325
EPS:
-65.4
Net Cash Flow:
$-6.64M
1W Performance:
-7.29%
1M Performance:
-2.17%
6M Performance:
-16.09%
1Y Performance:
-49.45%
1-Day Range:
$2.10
$2.40
1-Week Range:
$2.10
$2.4999
52-Week Range:
$1.72
$8.27
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
2.123 | 5.60M | 4.96M | -6.82M | -6.64M | -65.40 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
What recovery options are there for InMed Pharmaceuticals Inc.July 2025 Highlights & Technical Entry and Exit Alerts - newser.com
Order flow analysis tools used on InMed Pharmaceuticals Inc.2025 Performance Recap & Real-Time Buy Signal Alerts - newser.com
What dividend safety rating applies to InMed Pharmaceuticals Inc. (MWG) stockMarket Movement Recap & AI Enhanced Trading Signals - newser.com
Will a bounce in InMed Pharmaceuticals Inc. offer an exit2025 Price Momentum & Breakout Confirmation Alerts - newser.com
Using fundamentals and technicals on InMed Pharmaceuticals Inc.Weekly Trade Recap & Free Low Drawdown Momentum Trade Ideas - newser.com
InMed Pharmaceuticals appoints biotech veteran Neil Klompas to board By Investing.com - Investing.com Nigeria
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors - Investing News Network
InMed Pharmaceuticals Strengthens Board with Appointment of Industry Veteran Neil Klompas - TipRanks
InMed Pharmaceuticals appoints biotech veteran Neil Klompas to board - Investing.com
Can InMed Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 Action & Risk Controlled Swing Trade Alerts - newser.com
Published on: 2025-10-09 04:44:30 - newser.com
Will InMed Pharmaceuticals Inc. (MWG) stock justify high valuationJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - newser.com
Using flow based indicators on InMed Pharmaceuticals Inc.July 2025 Levels & Safe Capital Investment Plans - newser.com
Is InMed Pharmaceuticals Inc. stock bottoming outJuly 2025 Recap & Verified Swing Trading Watchlist - newser.com
What drives InMed Pharmaceuticals Inc stock priceMarket Sentiment Indicators & Fast Growing Portfolio - earlytimes.in
Reviewing CytoDyn (OTCMKTS:CYDY) and InMed Pharmaceuticals (NASDAQ:INM) - Defense World
What technical models suggest about InMed Pharmaceuticals Inc.’s comebackPortfolio Growth Summary & Fast Gaining Stock Strategy Reports - newser.com
InMed Pharmaceuticals Inc. stock momentum explainedGap Down & Weekly Market Pulse Updates - newser.com
Visual trend scoring systems applied to InMed Pharmaceuticals Inc.July 2025 Market Mood & Weekly Setup with High ROI Potential - newser.com
Why InMed Pharmaceuticals Inc. stock remains a top recommendation2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
Why InMed Pharmaceuticals Inc. stock could see breakout soon2025 Top Gainers & Risk Managed Trade Strategies - newser.com
Can Clean Science and Technology Limited Deliver Relative Outperformance to SectorPrice Momentum Alerts & Superior Trading Portfolio - earlytimes.in
What analysts say about InMed Pharmaceuticals Inc stockLong-Term Investment Plans & Fast Growing Capital Gains - earlytimes.in
How to use Fibonacci retracement on InMed Pharmaceuticals Inc.July 2025 Update & AI Forecasted Entry/Exit Points - newser.com
How to build a dashboard for InMed Pharmaceuticals Inc. stockWeekly Trend Summary & Entry Point Confirmation Signals - newser.com
Combining machine learning predictions for InMed Pharmaceuticals Inc.Quarterly Trade Summary & Fast Entry Momentum Trade Alerts - newser.com
How to escape a deep drawdown in InMed Pharmaceuticals Inc.July 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):